As an example, the recent launch of the redox-active fexinidazole in the Democratic Republic of Congo (DRC) to cure sleeping sickness was made possible thanks to excellent cure rates and low toxicity in treated patients infected by T. brucei gambiense or T. brucei rhodesiense. This compound has also been tested in murine models of Chagas disease.